Mime-Version: |
1.0 (Apple Message framework v730) |
Content-Type: |
text/plain; charset=ISO-8859-1; delsp=yes; format=flowed |
Date: |
Wed, 10 Aug 2005 12:06:53 +0800 |
Reply-To: |
|
Subject: |
|
From: |
|
In-Reply-To: |
<000901c59d57$f2e16320$0300a8c0@PC713697014916> |
Content-Transfer-Encoding: |
quoted-printable |
Sender: |
|
Parts/Attachments: |
|
|
On a study in which the conclusion states, in part, "Use of minimal
aliquots of L-aspartic acid and EHC for ß-glucuronidase inhibition
results in increased fecal bilirubin excretion and less jaundice,
without disruption of the breastfeeding experience. Decreased
jaundice in the W/C group, which lacked a ß-glucuronidase inhibitor,
suggests a different mechanism."
On 10/08/2005, at 11:02, Arly wrote:
> My guess is that the researchers have already been approached by a
> pharmaceutical/infant formula company.
A google/patent search reveals that the principal author already
holds a 2002 patent for the use of aspartic and/or malic acids in the
prevention of neonatal jaundice.
http://www.warf.org/ipstatus/P99139US.PDF
Lara Hopkins
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|